Enzo Biochem (ENZ) Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

February 3, 2021 8:31 AM EST
Get Alerts ENZ Hot Sheet
Price: $3.46 -0.57%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of Sclerostin”.

The new patent is a member of a broader U.S. and international patent family that also includes issued patents and pending patent applications for therapies including monoclonal antibodies and small synthetic peptides used to inhibit sclerostin in the treatment of bone disorders such as osteoporosis. Enzo’s patent focuses on polyclonal antibodies that bind a specific region of human sclerostin, a protein that is a negative regulator of bone growth. Sclerostin is produced in osteocytes, a type of bone cell, and is known to inhibit bone formation. The maintenance of bone over time requires a balance between the formation of new bone tissue and the breakdown and removal (resorption) of old bone tissue.

Elazar Rabbani, Ph.D., CEO of Enzo, commented: “This patent for polyclonal antibodies is the latest to arise from Enzo’s work demonstrating a critical regulatory role for two sulfation sites that are present in the human sclerostin protein. In addition to monoclonal and polyclonal antibodies targeting these regions, our patent portfolio also covers small synthetic peptides having sequences derived from the same regions, which have been shown to inhibit the interaction between sclerostin and its receptor and which, therefore, could potentially be used as therapeutics in the treatment of bone loss disorders such as osteoporosis.”

Osteoporosis is a medical condition that causes bones to become brittle (due to low bone density and quality), making them more susceptible to fractures. According to the International Osteoporosis Foundation (IOF), about 200 million people worldwide and 53 million people in the U.S. suffer from osteoporosis disorder and approximately 50% of women and 25% of men age 50 and older will break a bone due to osteoporosis. The global market for drugs to treat osteoporosis is expected to grow at a compounded annual growth rate of 4.4%, reaching $10.9 billion by 2026.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Litigation